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Abstract 
Objective: This study investigated c-Fos expression in two breast cancer cell lines (ER+/PR+ 
and HER2+ subtypes) and analysed toxic effect of radioiodine on those cells based on c-Fos 
expression for possibility of using radioiodine as breast cancer adjuvant therapy, particularly 
for patients who are resistance with existing therapy.    
Materials and Methods: This study uses breast cancer cell lines (MCF7 and SKBR3), and 
keratinocyte cell line (HaCaT) as control. To induce c-Fos expression, the cells were treated 
with epidermal growth factor (EGF) 50ng/ml, Adenosine tri-phosphate (ATP) 100μM and a 
combination of both for twenty-four hours and this was followed by 7.4 x 105 Becquerel/well 
of radioiodine (NaI-131). A quantitative real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) and immunocytofluoresence were used to assess c-Fos expressions.  
Results: It was found that c-Fos expression is only found in MCF-7 cells.  A combination of 
ATP and EGF has the potential to induce a 23 ±4 fold (p<0.05) increase of c-Fos mRNA and 
the values for ATP and EGF treatments were 1.17 ± 0.02 and 5 ± 2 respectively. Treatment 
of EGF or a combination of ATP and EGF reduces the reproductive ability of MCF-7 cell up 
to 100% after radioiodine exposure (p<0.05). It was found that inverse correlation between 
both c-Fos mRNA and protein expression with radioiodine effect on reproductive ability with 
r = - 0.90 and r = - 0.97 (p<0.05) respectively.  
Conclusion: There is a strong inverse correlation between the expressions of c-Fos with the 
effect of radioiodine in breast cancer cell. C-Fos expression is involved in cell death pathways 
after radioiodine exposure in MCF7 cells, while other pathway may correspond to cell death 
in SKBR3 cells.  
Keywords: Cell death, epidermal growth factor, adenosine tri-phosphate, sodium iodide 
symporter, reproductive ability 
I. INTRODUCTION 
     Breast cancer is the most commonly occurring cancer worldwide, with more than one 
million cases diagnosed annually and about 600,000 fatalities [1]. Breast cancer is a 
heterogeneous disease; thereby tumors at a similar stage and with similar histopathology can 
  
have diverse biological behavior and resulting responses to treatment [2,3]. Breast cancers 
are classified into five main subtypes; luminal A, luminal B, HER2, basal and normal like, 
according to the expression of hormone receptors [4]. Luminal A has a low recurrence score, 
and responds well to endocrine therapy. Luminal B has high recurrence score and is less 
responsive to endocrine therapy. However, the effectiveness of endocrine therapy has 
limitation, and around 30% of patients with Luminal A [5]. On the other side HER2+/neu 
subtype responds poorly to current chemotherapies [2]. New treatments, including 
radioiodine (131I) therapy are being developed to increase prognosis of breast cancer patients.  
     Radioiodine has been used for many decades in management thyroid cancer as adjuvant 
therapy after near-total thyroidectomy [6,7]. 131I is a radionuclide which emits ionizing 
radiation. It emits two types of radiation, gamma () and beta particle (β-) radiation, which 
are used to diagnose and treat a number of diseases [8]. Radiation of radioiodine has low 
linear energy transfer (LET), 0.25 KeV/µm approximately, and its penetration into soft tissue 
is about 1mm. A physical phase interaction between a β particle and the cell leads to cell 
destruction by direct and indirect mechanism. When radiation hits a DNA chain, the 
molecular structure can be change directly leading to cell death. A radiation can also hits 
cytoplasm cell which consists of almost 70% water to forms hydroxyl radicals. The free 
radicals in cytoplasm result the cell damage and caused cell death indirectly [8-12].  Free 
radicals induce cell cycle arrest by prolonging chromatin binding of phospho- extracellular 
signal-regulated kinase (ERK) and induce c-Fos transcription and regulates phosphorylated 
at C-terminal sites in chromatin. As a result, Fra-1 fails to attach to chromatin, and causing 
the cell to fail to express cyclin D1 and enter the S-phase of cycle cell [13]. 
     Ionizing radiation activates several signal pathways inside the cells and can induce either 
the death of the cell or cell proliferation [8,14]. In breast cancer cells which have an estrogen 
receptor α (ERα), the expression of E2F1 dependent on c-Fos plays a role in cell proliferation, 
differentiation and apoptosis [15].  Luminal A is breast cancer subtypes responses to 
hormonal therapy. However, Luminal A subtype is reported have a recurrence of the disease 
after being treated with tamoxifen around 30% of patients [5]. Furthermore, HER2+ subtype 
is reported has poorly response to current chemotherapies [2]. New therapy modalities are 
needed to be developed especially for those showed resistance.  In this study we assessed c-
  
Fos expression in two breast cancer cell lines (ER+/PR+ and HER2+ subtypes) and analysed 
toxic effect of radioiodine on those cells based on c-Fos expression for possibility of using 
radioiodine as breast cancer adjuvant therapy, particularly for patients who are resistance 
with existing therapy.    
 
II. MATERIAL AND METHODS 
Cell lines and culture condition 
     This study uses two types of breast cancer cell lines MCF7 (estrogen and progesterone 
positive receptors/ ER+ and PR+) and SKBR3 (human epidermal growth factor receptor 2/ 
HER2+) [16,17].   HaCaT cell line (a normal keratinocyte cell) as cell control. SKBR3 was 
supplied by the American Type Culture Collection (ATCC), MCF7 and HaCaT cell lines 
were gifted from the Faculty of Medicine, Universitas Padjadjaran, Bandung-Indonesia. 
MCF7 and HaCaT cells were cultured in a RPMI 1640 medium (Sigma-Aldrich). SKBR3 
was cultured in McCoy’s 5A medium (Sigma-Aldrich). All mediums were supplemented 
with 10% fetal bovine serum (Sigma-Aldrich), 1% Penicillin, 1% Streptomycin and 1% 
Amphotericin B. The cells were incubated at 37oC and supplied with 5% carbon dioxide 
(CO2) until 80% confluence was reached.  To induce c-fos expression, the cells were 
incubated in serum-free medium overnight and then treated with EGF 50ng/ml (Abcam 
#ab9697), ATP 100 µM (Sigma-Aldrich # 1388), and a combination of EGF and ATP for 
30, 45 and 60 minutes. Cells which did not receive any treatment after culturing were used 
as treatment controls.  
Quantitative Real-time reverse transcriptase –PCR (qRT-PCR) 
     The treated and untreated cells were harvested at an appropriate time by trypsinization. 
The cells were washed with PBS 2 twice and divided into PCR tube 4.105 cells/tube. The cell 
centrifuged at 1000 rpm for 4 minutes and storage at -80oC.  The total RNA was isolated 
from the cells using a RNeasy mini kit (Qiagen #74106) following the manufacturer’s 
instructions. Product C-Fos RNA was quantified using Nanodrop 2000. Five 5 ng of RNA 
  
reversely transcribed and analysed by one step real-time quantitative PCR using Rotor Gene 
Quantitect probe RT-PCR (Qiagen # 204443). The synthesis composition was quantitec 
probe RT MM 12.5 L, primer F 1L, Primer R 1L, Probe 1L, quantitec RT mix 0.25 L, 
RNAase free water 6.25L, and RNA 3L. Annealing temperature 60oC and amplified for 
40 cycles. C Fos forward: GCG GAC TAC GAG GCG TCA T. The reverse: GGA GGA GAC 
CAG AGT GGG C.  Probe: CTC CCC TGT CAA CAC ACA GGA CTT TTG C. β-actin 
forward: ACC GAG CGC GGC TAC AG. The reverse: CTT AAT GTC ACG CAC GAT 
TTC C. Probe: TTC ACC ACC ACG GCC GAG C. The c-Fos expression of treated cells to 
those untreated ones was analyzed using the method (2-∆∆CT) described by Livak et al [18]. 
qPCR assays were conducted in triplicate.  
Immunocytofluoresence 
The cells were seeded on coverslips in wells of a 24-well culture plate (2.5 105 cells /well). 
The treated and untreated cells were then rinsed three times with phosphate buffer saline 
(PBS) and fixed using 4% paraformaldehyde for 15 minutes at room temperature. The cells 
were rinsed twice with an ice-cold PBS and then incubated with 0.25% Triton X-100 in PBS 
for ten minutes. The cells then were rinsed with ice-cold PBS three times and incubated with 
fluorescein-isothiocyanate (FITC) for 15 minutes and then were rinsed twice with an ice-cold 
PBS and subsequently incubated overnight with 5µg/ml rabbit polyclonal antibody anti- cfos 
(Abcam, # ab83816) at 4oC. The following day the cells were rinsed three times with PBS 
and then incubated with goat polyclonal antibody to rabbit IgG 1:1500 (ab 6717) for one 
hour at room temperature. The coverslips were mounted with fluoroshield mounting medium 
containing 4’,6-diamidino-2-phenylindole (DAPI). The slides were inspected under a 
immunofluorescence microscope (Olympus BX51) with 200x magnification. Cells which 
were incubated with a secondary antibody only were used as a negative control. To assess 
the intensity of staining, IHC staining results were graded on a 0 to 3 scale:  0 being no 
staining; 1 weak nuclear staining faintly perceptible at high power; 2 is moderate nuclei 
staining; and 3 is the nuclei displaying strong staining [19]. 
 
  
Clonogenic assay 
     A clonogenic assay was used to assess the differences in reproductive ability (capacity of 
cells to split and produce progeny) between cells that have undergone exposure to radioiodine 
radiation and control/untreated cells. The treated and untreated cells were grown in twelve-
well culture plates (2.5x105 cell/well) for 24 hours. The cells then were incubated for seven 
hours in 5% CO2 at 37°C with HBSS containing 7.4 x 105 Becquerel/well of NaI-131 
(BATAN, Indonesia) and 10mM HEPES (pH 7.3). The reaction was terminated by removing 
the NaI-131 containing medium and the cells were washed twice with cold HBSS. The cells 
were trypsinized, counted, and plated at densities of 500 and 1000 cells/well with growth 
medium in six-well culture plates. After that, the cells were grown for ten days. Macroscopic 
colonies formed were counted on the tenth day. Reproductive ability was calculated as the 
percentage of colonies in plates treated with NaI-131 compared to untreated ones.  
Statistical analysis 
     Collected results are expressed as mean  SD. Quantitative data were analyzed by 
ANOVA to compare means between groups followed by a Turkey test.  Qualitative data were 
analyzed using Mann-Whitney, and p<0.05 was considered statistically significant. 
Correlation between c-Fos expression with effect of radioiodine was tested with Spearman’s 
rho, and p<0.05 was considered significant.  
 
III. RESULTS AND DISCUSSION 
 mRNA C-Fos expression by qRT-PCR 
     The expression of mRNA c-Fos was demonstrated in MCF7 cell. However, the expression 
was not detected in treated and untreated SKBR3 and HaCaT cells. The treatment with ATP, 
EGF or a combination of both for 30, 45 induced mRNA c-Fos in MCF-7 cell (Figure 1). 
ATP and EGF combined treatment for 30 minutes induced a c-Fos mRNA level of 23 ± 4 
(p<0.05), and the values for ATP and EGF treatments were 1.17 ± 0.02 and 5 ± 2 respectively.  
The level of mRNA c-Fos started to reduce on 60 minutes of treatment. (Figure 2).  
  
 
Figure 1: C-Fos gene is 231 base-pair in MCF-7 cells treated with ATP, EGF, and a 
combination of both for 30 minutes duration (right to left) 
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Figure 2: mRNA c-Fos expression in the MCF-7 cell line. The level of expression increases 
on 30 and 45 minutes of induction with ATP, EFG or a combination of the two.  A 
combination of ATP and EGF increases c-Fos expression at a significantly higher 
level (p<0.05) compared to that of ATP or EGF alone. Duration of treatment longer 
than 45 minutes did not increase expression. 
Immunocytofluoresence analysis of c-Fos protein expression 
     c-Fos protein was detected in the nuclei of MCF7 cells (Figure 3). Consistent with PCR 
results, SKBR3 and HaCaT cells did not express c-Fos protein.  The c-Fos expression level 
increased 30 to 45 minutes after treatment and reduced after 45 minutes treatment. This same 
condition consistence with the c-Fos mRNA expression.  Means of c-Fos increased after 30 
minutes induction of ATP, EGF and combination of both are 30.5, 30, 30.5             
respectively p=0.04. Means of c-Fos increased after 45 minutes induction of ATP, EGF and 
combination of both are  30.7, 20.5, 30 respectively p=0.02. Means of c-Fos after 60 
minutes of induction were not different compare to control are 10.7, 10.5, 10.7 for ATP, 
EGF and combination of both respectively (figure 4).  
 
 
  
 
Figure 3    C-Fos protein expression shown at nuclei as green staining by FITC and a blue 
staining by DAPI at 200x magnification. The highest intensity of staining was 
shown on 30 minutes of treatment. C-Fos protein expression by ATP (A); EGF 
(B); and a combination of ATP+EGF (C); control (D). The expressions were 
persistent 30 to 45 minutes of treatment and started to reduce at 60 minutes.  
 
  
 
Figure 4:  Analysis c-Fos protein expression in MCF7 cell line increased on 30 and 45 
minutes all treatments significantly. The expression reduced on 60 minutes of all 
treatments.  
Clonogenic assay after radioiodine radiation 
     Clonogenic assay was used to assessed cytotoxic effect of radioiodine on cell lines. The 
effect was calculated based on cell reproductive ability. Radioiodine exposure to the cells 
reduced the reproductive ability as 23 ± 5%, 53 ± 9% and 99 ± 4% for MCF7, SKBR3 and 
HaCaT respectively (Figure 5). 
0
0.5
1
1.5
2
2.5
3
3.5
4
Control ATP EGF ATP+EGF
30 minutes 45 minutes 60 minutes
*
* *
*
*
* 
  
 
Figure 5:   Reproductive ability after radioiodine exposure of three cell lines cultured in six 
well culture plates and treated with ATP, EGF and combination of ATP and EGF 
for 30 minutes prior to addition of 7.4x105 Becquerel/well NaI-131. The control 
group received 7.4x105 Becquerel/well NaI-131 alone. Radioiodine exposure 
reduced reproductive ability of MCF7 and SKBR3 cells significantly more than 
that of HaCaT cells (p<0.05).  Treatment of MCF7 and SKBR3 with EGF or a 
combination ATP and EGF prior to radioiodine exposure resulted in a total 
discontinuation of reproductive ability p<0.05. Radioiodine exposure alone had 
almost no effect of on reproductive ability HaCaT cells, but ATP, EGF or a 
combination of both treatments prior radioiodine exposure resulted in a 
significant effect on the reproductive ability of the HaCaT cells (p<0.05).   
 
     Interestingly, radioiodine expose has very minimal effect on HaCaT cell reproductive 
ability. (Figure 5). Radioiodine exposure to MCF7 and SKBR3 cells reduced cell 
reproductive ability compared to HaCaT cells (p<0.05). ATP and/or EGF treatment along 
with radioiodine in SKBR3 cell line effectively eliminated the cell's reproductive ability.  
Furthermore, the reproductive ability of HaCaT cells after ATP, EGF or ATP/EGF 
combination treatment and radioiodine treatment were 38 ± 3%, 5 ± 0.3% and 2 ± 0.3% 
respectively. The treatments significant reduced of cell reproductive ability, p<0.05 (Figure 
5).    
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     We find an inverse correlation between the effect of radioiodine with mRNA and protein 
c-Fos levels in MCF-7 cells with r = - 0.906 and r = - 0.973 (p < 0.05) respectively. Treatment 
of ATP, EGF and combination of both increased the effect of radioiodine in suppressing the 
reproductive ability of the cells. 
     Estrogen receptors (ERs) play a pivotal role in the growth and maintenance of both normal 
breast cells and breast cancer cells. Estrogen receptors control transcription via direct and 
indirect DNA interactions. The direct pathway involves estrogen-activated ER binding 
estrogen-responsive elements and the indirect pathway involves liganded ERs which are 
bonded to DNA by interacting with activator protein-1 (AP-1). Heterodimers of c-Jun and c-
Fos form AP-1 and it plays an important role in regulating breast cancer cell proliferation 
differentiation and proliferation and apoptotic process [15,20]. In our study, c-Fos expression 
was only found in the MCF7 breast cancer cell line. The expression did not detect in SKBR3 
and HaCaT cell line. SKBR3 is HER2+ and ER-/PR- receptors. It may also be undetectable 
of c-Fos related to the absence of estrogen receptor [16].   
     NIS plays an important role to taken up iodine from extracellular and accumulated it 
intracellular [21]. Furthermore, NIS expression has an inverse correlation with c-Fos 
expressions [22]. Furthermore, the reproductive ability of cells after radioiodine exposure 
reduced more markedly in MCF7 cell compare to SKBR3 and HaCaT cells even though 
MCF7 does not express Natrium Iodide Symporter (NIS) as radioiodine transporter [23].  In 
this study, we found strong inverse correlation between c-Fos expression and reproductive 
ability of the cell after radioiodine exposure. We assumed, c-Fos increases cell sensitivity 
toward β radiation of radioiodine thru bystander effect that lead indirect cell death by produce 
the hydroxyl free radicals [8]. Besides of that molecule of iodine has effect as 
antiproliferative agent [24]. A report that the c-Fos/miR-22/MDC1 pathway plays a major 
role as a sensitizer in cancer therapy. C-Fos and miR-22 up-regulation causes a down-
regulation of mediator DNA damage checkpoint protein 1 (MDC1). MDC1 plays a central 
role in the DNA damage response. It orchestrates double strand break (DBS) repairs and 
checkpoint activation that contribute to tumorigenesis. Thus, up-regulation of the c-Fos/miR-
22/MDC1 pathway increases tumor sensitivity to anticancer drugs or radiation therapy 
  
enhancing the therapeutic efficacy [25]. Further investigation is needed to uncover the role 
of c-Fos in apoptosis mechanism.  
     Furthermore, c-Fos expression is inducible. Fenretine (a synthetic retinoid) exhibits an 
ability to induce c-Fos, and the effect increases apoptosis rate in ovarian cancer cell lines 
[20]. Adenosine triphosphate (ATP) and epidermal growth factor (EGF) both moderately 
induce c-Fos expression, and the combination both ATP and EGF synergistically activates 
the extra-cellular signal-regulated kinase (ERK) pathway to increase c-Fos expression in 
MCF7 [26]. Our study shows that ATP and EGF alone or in combination significantly 
increase c-Fos protein, and this induction together with radioiodine treatments, 
synergistically increases cell death in MCF7 cell.  
     On the other hand, although SKBR3 cell did not express c-Fos but ATP and EGF 
treatments increased cell death after radioiodine exposure in the cell. We assumed the 
treatments stimulate the cells to activate the mitogen-activated protein kinase (MAPK) 
pathway.  Increasing of the MAPK pathway inhibits DNA synthesis by expressing cyclin-
dependent kinase inhibitor protein p21 [13].  We also find that treatment with ATP, EGF or 
combination of ATP and EGF increase the toxic effect of radioiodine in HaCaT cell line. 
Further studies are needed to elaborate the role of those treatments in cell death pathways. It 
seems different breast cancer subtypes have different pathways for cell death mechanisms. 
     Cell death mechanism in SKBR3 cells after radioiodine exposure is different from that in 
MCF7 cells. SKBR3 cell express NIS as transporter [22]. This transporter mediates 
radioiodine uptake [21]. A study reported that increasing NIS expression in ER-negative 
breast cancers boost the radioiodine uptake and susceptibility toward radioiodine radiation 
[3]. NIS enables radioiodine to be taken up and accumulated inside the cells. It emits β 
radiation which has a penetration of about 1 mm and hits DNA directly and water molecules 
to produce free radicals [8]. Depend on the dose, the radiation can produce DNA lesions such 
as double-strand breaks (DBSs) which appear to have a role cell cycle arrests and apoptosis 
[27,28]. Furthermore, besides damaging DNA directly, radioiodine exposure produces free 
radicals that caused indirect cell death.  Interestingly, it has been found that HaCaT cells are 
  
not affected by radioiodine, even at the levels of radioiodine uptake that are higher than in 
MCF7 cell [23]. The effect of radioiodine in that dose in HaCaT cell was un-significantly 
and this may be that normal cell more resistance toward radiation than the cancer ones.  
 
IV. CONCLUSION     
     MCF7 cell line represented luminal A subtype expresses c-Fos and treatment of ATP and 
EGF increase the expression. C-Fos increases MCF7 cell sensitivity toward radioiodine 
exposure. A strong inverse correlation between the expressions of c-Fos and cell reproductive 
ability after radioiodine exposure. This result indicating a considerable potential of 
radioiodine for breast cancer treatment including luminal A subtype.  Further studies are 
needed to elaborate the effect of radioiodine in different breast cancer subtypes. 
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